[Effect of the Degree of Myelofibrosis on the Therapeutic Efficacy and Survival in Patients with Myelodysplastic Syndromes].

View at publisher Summarise with VIRAT
Authors: Rui-Ping Li, Yan-Ping Ma
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

OBJECTIVE: To investigate the effect of the degree of myelofibrosis (MF) on clinical characteristics, therapeutic efficacy of hypomethylating agents (HMA) and survival in patients with myelodysplastic syndromes (MDS). METHODS: The clinical data of 103 patients with newly diagnosed MDS who received HMA treatment in the Department of Hematology of the Second Hospital of Shanxi Medical University from January 1, 2016 to July 15, 2021 were retrospectively analyzed. The patients were divided into three groups according to the degree of fibrosis in bone marrow biopsy: MDS-MF0, MDS-MF1, and MDS-MF2/3. The clinical characteristics, efficacy and survival were compared among three groups. Logistic regression and Cox regression analyses were employed to identify factors affecting the efficacy and prognosis. RESULTS: =0.057). Multivariate analysis showed that an increased proportion of bone marrow blasts and complex karyotype were independent risk factors for OS, while more than 4 cycles of treatment was an independent protective factor for OS. The degree of myelofibrosis did not have independent prognostic significance. CONCLUSION: MDS patients with moderate to severe myelofibrosis have more severe anemia and more common -5/del(5q) chromosome abnormalities. MDS patients with myelofibrosis had a lower ORR to HMA therapy, but there was no significant difference in ORR among MDS patients with different degrees of myelofibrosis. In the context of HMA treatment, the myelofibrosis has an adverse effect on the survival of MDS patients, though it did not show independent prognostic significance.

Fields of Study & Subjects

Acute Myeloid Leukemia Research Hematopoietic Stem Cell Transplantation Hematological disorders and diagnostics

Publication details

Journal / source
PubMed
Volume
34
Issue
1
Pages
142–153
Publication date
1 February 2026
Language
ZH